Sabitlenmiş Tweet
🔔SELECT Trial now enrolling
✅Stage II-III ER+/HER2-/Node+ EBC with Low Oncotype RS 0-25
💟Patient Choice ± adjuvant chemotherapy + ribociclib (Kisqali) + optimized ET
🎯 Chemo impact on discontinuation rate of ribo
❣️Support by BCRF, Novartis (ribo provided as part of study)
Yale Cancer Center@YaleCancer
Dr. Jing Du @YaleBreast highlights the phase II SELECT trial #SABCS25 (NCT06953882) studying ribociclib + endocrine therapy in ER+/HER2−, node-positive #breastcancer with low genomic risk. The study compares 1-year ribociclib discontinuation, survival, QOL, and decisions between those receiving chemo vs. no chemo. Recruitment is ongoing. @OncoAlert @AdrianaKahnMD @ncasasanta @maryam_lustberg
English
